Evogene Ltd.

Equities

EVGN

IL0011050551

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 08:49:49 2024-05-12 am EDT			5-day change	1st Jan Change
258.7 ^ILa	-2.74%		-3.18%	-13.71%

Apr. 02	Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd	CI
Mar. 20	Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq	MT

Lavie Bio Announces the Appointment of Russ Putland as Vice President Commercial

May 25, 2021 at 07:00 am EDT

PR Newswire , May 25, 2021, 12:00:00 PM BST - Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (TASE: EVGN), announced the appointment of Mr. Russ Putland as Vice President Commercial.

Latest news about Evogene Ltd.

Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd	Apr. 02	CI
Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq	Mar. 20	MT
Transcript : Evogene Ltd., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Evogene Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules	Mar. 06	MT
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides	Mar. 06	CI
Casterra Announces New Agreements with Subsidiary of Evogen Ltd., to Meet Growing Demand for Its Elite Castor Seed Varieties	Mar. 05	CI
Evogene Files $200 Million Mixed Shelf	Mar. 01	MT
Evogene Ltd. and Verb Biotics LLC Enters into Collaboration Agreement	Feb. 06	CI
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024	Dec. 19	CI
Transcript : Evogene Ltd., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Earnings Flash (EVGN) EVOGENE Posts Q3 Revenue $3.8M	Nov. 15	MT
Evogene Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Colors Farm Ltd, Evogene Ltd. and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology	23-10-31	CI
Alliance Global Starts Evogene at Buy With $1.85 Price Target	23-10-02	MT
Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	23-08-18	MT
Transcript : Evogene Ltd., Q2 2023 Earnings Call, Aug 17, 2023	23-08-17
Earnings Flash (EVGN) EVOGENE Posts Q2 Revenue $654,000	23-08-17	MT
Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery	23-07-25	CI
Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program	23-07-19	CI
Evogene Expects to Raise $8.5 Million in Gross Proceeds From Registered Direct Offering; Shares Fall	23-07-17	MT
Evogene's Lavie Bio Says Corteva to Develop, Commercialize Lead Fungicide Product Candidates	23-07-17	MT
Evogene Subsidiary Receives Additional $2.2 Million in Purchase Orders for Castor Seeds	23-07-03	MT

Chart Evogene Ltd.

Duration

Period

More charts

Company Profile

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOGENE LTD.	-13.71%	35.18M
MODERNA, INC.	+28.34%	48.16B
IQVIA HOLDINGS INC.	-0.43%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+10.99%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B
BIO-TECHNE CORPORATION	+8.59%	12.92B
MEDPACE HOLDINGS, INC.	+29.98%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.77B

Other Biotechnology & Medical Research